Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies
Author:
Publisher
Wiley
Subject
Health, Toxicology and Mutagenesis,Genetics(clinical),Epidemiology
Reference95 articles.
1. Preliminary results of Phase II trial of clofarabine with parenteral busulfan (Clo/Bu) followed by allogeneic related or unrelated donor transplantation for the treatment of hematologic malignancies;Agura;Biol Blood Marrow Transplant,2010
2. Comparative outcome of nonmyeloablative and myeloablative hematopoietic cell transplantation for patients older than 50 years of age;Alyea;Blood,2005
3. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplant conditioning therapy: A phase I study;Andersson;Biol Blood Marrow Transplant,2000
4. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia;Andersson;Biol Blood Marrow Transplant,2002a
5. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study;Andersson;Biol Blood Marrow Transplant,2002b
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Autologous engineered T cell receptor therapy in advanced cancer;Human Vaccines & Immunotherapeutics;2023-12-15
2. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells;Frontiers in Oncology;2023-11-23
3. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer;Cancer Immunology Research;2023-05-12
4. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation;Bone Marrow Transplantation;2022-05-24
5. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells;Oncotarget;2022-02-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3